{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:31Z","timestamp":1772166091181,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["Immunology Research Center (grant No. 61270)"],"award-info":[{"award-number":["Immunology Research Center (grant No. 61270)"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BC) is the most invasive cancer with different subtypes that its metabolism is unique compared with normal cells. Glutamine is considered critical nutrition that many cancer cells, particularly BC cells, are dependent on it for growth and proliferation. Therefore, targeting glutamine metabolism, especially enzymes that are related to this pathway, can be beneficial to design anti-cancer agents. Recent evidence has shown that microRNAs (miRNAs), with a short length and single-strand properties, play a prominent role in regulating the genes related to glutamine metabolism, which may control the development of cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In silico analysis confirmed that miR-513c and miR-3163 might be involved in glutamine metabolism. The expression level of these two miRNAs was evaluated in eighty BC tissues and normal adjacent tissues. Furthermore, GSE38167, GSE38867, GSE42128, GSE45666, and GSE53179 were employed from gene expression omnibus (GEO). The Limma package was utilized to identify differentially expressed miRNAs (DEMs) of mentioned datasets to evaluate miR-513c and miR-3163 expression. Further, in silico analysis was utilized to predict the potential biological processes and molecular pathways of miR-513c and miR-3163, based on their target genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In silico studies revealed top categories of biological processes and cellular pathways that might play a critical role in metabolism reprogramming and cancer development and were target genes for miR-513c and miR-3163. The current study showed that miR-513c (\n                      <jats:italic>p<\/jats:italic>\n                      value\u2009=\u20090.02062 and FC\u2009=\u2009\u2009\u2212\u20092.3801) and miR-3163 (\n                      <jats:italic>p<\/jats:italic>\n                      value\u2009=\u20090.02034 and FC\u2009=\u2009\u2009\u2212\u20092.3792) were downregulated in tumor tissues compared to normal adjacent tissues. The analysis of GEO microarray datasets showed that miR-513c was downregulated in GSE38167, GSE38867, GSE42128, GSE45666 and GSE53179, whereas there was a significant downregulation of miR-3163 in only two studies, including GSE38867 and GSE42128 that they were in accordance with our experimental results. Furthermore, the subgroup analysis did not show any substantial relationship between expression levels of these two miRNAs and factors such as age, family history of cancer, and abortion history.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MiR-513c and miR-3163 were downregulated in BC tissues, which might serve as tumor suppressors. They are suggested as potential therapeutic targets for patients with BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-021-01029-3","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T12:30:10Z","timestamp":1625661010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The expression of miR-513c and miR-3163 was downregulated in tumor tissues compared with normal adjacent tissue of patients with breast cancer"],"prefix":"10.1186","volume":"14","author":[{"given":"Soheila","family":"Delgir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khandan","family":"Ilkhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Safi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Rahmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Montazari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Zaynali-Khasraghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Seif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milad","family":"Bastami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-3594","authenticated-orcid":false,"given":"Mohammad Reza","family":"Alivand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"issue":"5","key":"1029_CR1","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1002\/jcp.26116","volume":"233","author":"M Zare","year":"2018","unstructured":"Zare M, et al. Aberrant miRNA promoter methylation and EMT-involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol. 2018;233(5):3729\u201344.","journal-title":"J Cell Physiol"},{"issue":"6","key":"1029_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1029_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000503219","volume":"14","author":"U Dafni","year":"2019","unstructured":"Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: incidence and survival across European countries. Breast Care. 2019;14(6):344\u201353.","journal-title":"Breast Care"},{"issue":"8","key":"1029_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol"},{"issue":"2","key":"1029_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.15296\/ijwhr.2019.23","volume":"7","author":"B Baradaran","year":"2019","unstructured":"Baradaran B, Hajiasgharzadeh K. Breast cancer among young women in Iran. Int J Women\u2019s Health Reprod Sci. 2019;7(2):140.","journal-title":"Int J Women\u2019s Health Reprod Sci"},{"issue":"1","key":"1029_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"P Fuentes","year":"2020","unstructured":"Fuentes P, et al. ITGB3-mediated uptake of small extracellular vesicles facilitates intercellular communication in breast cancer cells. Nat Commun. 2020;11(1):1\u201315.","journal-title":"Nat Commun"},{"issue":"8","key":"1029_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1586\/era.12.85","volume":"12","author":"CK Ng","year":"2012","unstructured":"Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert Rev Anticancer Ther. 2012;12(8):1021\u201332.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1029_CR8","doi-asserted-by":"publisher","first-page":"108366","DOI":"10.1016\/j.mrrev.2021.108366","volume":"787","author":"S Delgir","year":"2021","unstructured":"Delgir S, et al. The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutat Res Rev Mutat Res. 2021;787:108366.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"2","key":"1029_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/his.13334","volume":"72","author":"R El Ansari","year":"2018","unstructured":"El Ansari R, et al. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 2018;72(2):183\u201390.","journal-title":"Histopathology"},{"issue":"3","key":"1029_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/ERC-12-0398","volume":"20","author":"S Kim","year":"2013","unstructured":"Kim S, et al. Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 2013;20(3):339\u201348.","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"1029_CR11","doi-asserted-by":"publisher","first-page":"e0185092","DOI":"10.1371\/journal.pone.0185092","volume":"12","author":"M Lampa","year":"2017","unstructured":"Lampa M, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS ONE. 2017;12(9):e0185092.","journal-title":"PLoS ONE"},{"issue":"6","key":"1029_CR12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-15-2038","volume":"76","author":"M Bacci","year":"2016","unstructured":"Bacci M, et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Can Res. 2016;76(6):1615\u201326.","journal-title":"Can Res"},{"key":"1029_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/1871520620666200910123428","volume":"21","author":"K Ilkhani","year":"2020","unstructured":"Ilkhani K, et al. The engaged role of tumor microenvironment in cancer metabolism: focusing on cancer-associated fibroblast and exosome mediators. Anti Cancer Agents Med Chem. 2020;21:254\u201366.","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"9","key":"1029_CR14","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.1172\/JCI69600","volume":"123","author":"CT Hensley","year":"2013","unstructured":"Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Investig. 2013;123(9):3678\u201384.","journal-title":"J Clin Investig"},{"issue":"14","key":"1029_CR15","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-14-1200","volume":"21","author":"P Korangath","year":"2015","unstructured":"Korangath P, et al. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin Cancer Res. 2015;21(14):3263\u201373.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1029_CR16","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1038\/oncsis.2017.70","volume":"6","author":"A Marshall","year":"2017","unstructured":"Marshall A, et al. ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. Oncogenesis. 2017;6(7):e367\u2013e367.","journal-title":"Oncogenesis"},{"issue":"7239","key":"1029_CR17","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nature07823","volume":"458","author":"P Gao","year":"2009","unstructured":"Gao P, et al. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762\u20135.","journal-title":"Nature"},{"key":"1029_CR18","doi-asserted-by":"publisher","first-page":"153220","DOI":"10.1016\/j.prp.2020.153220","volume":"216","author":"Y Pahlavan","year":"2020","unstructured":"Pahlavan Y, et al. Prominent roles of microRNA-142 in cancer. Pathol Res Pract. 2020;216:153220.","journal-title":"Pathol Res Pract"},{"key":"1029_CR19","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2174\/1871520620666200903145939","volume":"21","author":"A Safi","year":"2020","unstructured":"Safi A, et al. miRNAs modulate the dichotomy of cisplatin resistance or sensitivity in breast cancer: an update of therapeutic implications. Anti Cancer Agents Med Chem. 2020;21:1069\u201381.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"1029_CR20","doi-asserted-by":"publisher","first-page":"153452","DOI":"10.1016\/j.prp.2021.153452","volume":"21","author":"K Nejati","year":"2021","unstructured":"Nejati K, Alivand M, Arabzadeh A. MicroRNA-22 in female malignancies: focusing on breast, cervical, and ovarian cancers. Pathol Res Pract. 2021;21:153452.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"1029_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/cas.14764","volume":"112","author":"MH Soheilifar","year":"2021","unstructured":"Soheilifar MH, et al. Concomitant overexpression of mir-182-5p and mir-182-3p raises the possibility of IL-17\u2013producing Treg formation in breast cancer by targeting CD3d, ITK, FOXO1, and NFATs: A meta-analysis and experimental study. Cancer Sci. 2021;112(2):589.","journal-title":"Cancer Sci"},{"issue":"3","key":"1029_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/1756-185X.13410","volume":"22","author":"M Khoshmirsafa","year":"2019","unstructured":"Khoshmirsafa M, et al. Elevated expression of miR-21 and miR-155 in peripheral blood mononuclear cells as potential biomarkers for lupus nephritis. Int J Rheum Dis. 2019;22(3):458\u201367.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"1029_CR23","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.1002\/jcb.26802","volume":"119","author":"K Zhang","year":"2018","unstructured":"Zhang K, et al. LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem. 2018;119(7):6045\u201356.","journal-title":"J Cell Biochem"},{"issue":"21","key":"1029_CR24","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1158\/1078-0432.CCR-14-1566","volume":"21","author":"B-D Wang","year":"2015","unstructured":"Wang B-D, et al. Identification and functional validation of reciprocal microRNA\u2013mRNA pairings in African American prostate cancer disparities. Clin Cancer Res. 2015;21(21):4970\u201384.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1029_CR25","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.3892\/mmr.2015.3913","volume":"12","author":"J Xu","year":"2015","unstructured":"Xu J, Sun T, Hu X. microRNA-513c suppresses the proliferation of human glioblastoma cells by repressing low-density lipoprotein receptor-related protein 6. Mol Med Rep. 2015;12(3):4403\u20139.","journal-title":"Mol Med Rep"},{"issue":"4","key":"1029_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/CBM-170577","volume":"20","author":"H-L Xia","year":"2017","unstructured":"Xia H-L, et al. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomark. 2017;20(4):589\u201396.","journal-title":"Cancer Biomark"},{"issue":"4","key":"1029_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/mt.2014.247","volume":"23","author":"T-H Hsieh","year":"2015","unstructured":"Hsieh T-H, et al. HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells. Mol Ther. 2015;23(4):656\u201366.","journal-title":"Mol Ther"},{"issue":"18","key":"1029_CR28","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1158\/1078-0432.CCR-09-0385","volume":"15","author":"H Yang","year":"2009","unstructured":"Yang H, et al. MicroRNA expression signatures in Barrett\u2019s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15(18):5744\u201352.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1029_CR29","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3346\/jkms.2016.31.6.836","volume":"31","author":"M Jia","year":"2016","unstructured":"Jia M, et al. Silencing of ABCG2 by microRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. J Korean Med Sci. 2016;31(6):836\u201342.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1029_CR30","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1007\/s13277-015-4151-2","volume":"37","author":"L Su","year":"2016","unstructured":"Su L, et al. Skp2 regulates non-small cell lung cancer cell growth by Meg3 and miR-3163. Tumor Biol. 2016;37(3):3925\u201331.","journal-title":"Tumor Biol"},{"issue":"9","key":"1029_CR31","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1373\/clinchem.2018.299651","volume":"65","author":"S Subramaniam","year":"2019","unstructured":"Subramaniam S, et al. Emergence of MicroRNAs as key players in cancer cell metabolism. Clin Chem. 2019;65(9):1090\u2013101.","journal-title":"Clin Chem"},{"issue":"5","key":"1029_CR32","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134(5):703\u20137.","journal-title":"Cell"},{"key":"1029_CR33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2174\/1871520620666200924105352","volume":"21","author":"K Ilkhani","year":"2021","unstructured":"Ilkhani K, et al. Clinical and in silico outcomes of miR-130a-5p and miR-615-3p expression in tumor compared with non-tumor adjacent tissues of patients with BC. Anti Cancer Agents Med Chem. 2021;21:927\u201335.","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"4","key":"1029_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.drudis.2013.10.008","volume":"19","author":"WP Katt","year":"2014","unstructured":"Katt WP, Cerione RA. Glutaminase regulation in cancer cells: a druggable chain of events. Drug Discov Today. 2014;19(4):450\u20137.","journal-title":"Drug Discov Today"},{"issue":"4","key":"1029_CR35","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/his.14014","volume":"76","author":"BK Masisi","year":"2020","unstructured":"Masisi BK, et al. The role of glutaminase in cancer. Histopathology. 2020;76(4):498\u2013508.","journal-title":"Histopathology"},{"key":"1029_CR36","doi-asserted-by":"publisher","first-page":"107458","DOI":"10.1016\/j.compbiolchem.2021.107458","volume":"92","author":"Y Rahmati","year":"2021","unstructured":"Rahmati Y, Alivand M, Mollanoori H. MiR-330-3p and miR-485-5p as biomarkers for glioblastoma: an integrated bioinformatics and experimental study. Comput Biol Chem. 2021;92:107458.","journal-title":"Comput Biol Chem"},{"issue":"311","key":"1029_CR37","first-page":"311","volume":"23","author":"YZ Xiong","year":"2018","unstructured":"Xiong YZ, Wang J, Cao X. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomark. 2018;23(311):311.","journal-title":"Cancer Biomark"},{"issue":"67","key":"1029_CR38","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.18632\/oncotarget.27327","volume":"10","author":"E Zografos","year":"2019","unstructured":"Zografos E, et al. Prognostic role of microRNAs in breast cancer: a systematic review. Oncotarget. 2019;10(67):7156.","journal-title":"Oncotarget"},{"issue":"7","key":"1029_CR39","first-page":"927","volume":"21","author":"K Ilkhani","year":"2021","unstructured":"Ilkhani K, et al. Clinical and in silico outcomes of the expression of miR-130a-5p and miR-615-3p in tumor compared with non-tumor adjacent tissues of patients with BC. Anti Cancer Agents Med Chem (Former Curr Med Chem Anti Cancer Agents). 2021;21(7):927\u201335.","journal-title":"Anti Cancer Agents Med Chem (Former Curr Med Chem Anti Cancer Agents)"},{"issue":"16","key":"1029_CR40","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00018-017-2508-y","volume":"74","author":"L-F Zhang","year":"2017","unstructured":"Zhang L-F, Jiang S, Liu M-F. MicroRNA regulation and analytical methods in cancer cell metabolism. Cell Mol Life Sci. 2017;74(16):2929\u201341.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1029_CR41","doi-asserted-by":"publisher","first-page":"e2529","DOI":"10.1038\/cddis.2016.440","volume":"8","author":"M-N Zhan","year":"2018","unstructured":"Zhan M-N, et al. MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Cell Death Dis. 2018;8(1):e2529\u2013e2529.","journal-title":"Cell Death Dis"},{"key":"1029_CR42","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3389\/fonc.2019.01404","volume":"9","author":"A Pedroza-Torres","year":"2019","unstructured":"Pedroza-Torres A, et al. microRNAs in tumor cell metabolism: Roles and therapeutic opportunities. Front Oncol. 2019;9:1404.","journal-title":"Front Oncol"},{"issue":"16","key":"1029_CR43","doi-asserted-by":"publisher","first-page":"25928","DOI":"10.18632\/oncotarget.15237","volume":"8","author":"D Lin","year":"2017","unstructured":"Lin D, et al. Metabolic heterogeneity signature of primary treatment-naive prostate cancer. Oncotarget. 2017;8(16):25928.","journal-title":"Oncotarget"},{"issue":"1","key":"1029_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1476-4598-8-128","volume":"8","author":"S Mittal","year":"2009","unstructured":"Mittal S, et al. Cooperation of Notch and Ras\/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer. 2009;8(1):128.","journal-title":"Mol Cancer"},{"key":"1029_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cellsig.2017.09.025","volume":"42","author":"Y Jia","year":"2018","unstructured":"Jia Y, et al. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Cell Signal. 2018;42:165\u201375.","journal-title":"Cell Signal"},{"issue":"2","key":"1029_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","volume":"69","author":"OK Mirzoeva","year":"2009","unstructured":"Mirzoeva OK, et al. Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69(2):565\u201372.","journal-title":"Cancer Res"},{"issue":"20","key":"1029_CR47","doi-asserted-by":"publisher","first-page":"7705","DOI":"10.1073\/pnas.1116573109","volume":"109","author":"K Thangavelu","year":"2012","unstructured":"Thangavelu K, et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf\u2013Mek\u2013Erk signaling in cancer cell metabolism. Proc Natl Acad Sci. 2012;109(20):7705\u201310.","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"1029_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1349-7006.2010.01779.x","volume":"102","author":"M Souzaki","year":"2011","unstructured":"Souzaki M, et al. Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer. Cancer Sci. 2011;102(2):373\u201381.","journal-title":"Cancer Sci"},{"issue":"8","key":"1029_CR49","doi-asserted-by":"publisher","first-page":"e0182679","DOI":"10.1371\/journal.pone.0182679","volume":"12","author":"J Li","year":"2017","unstructured":"Li J, et al. Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism. PLoS ONE. 2017;12(8):e0182679.","journal-title":"PLoS ONE"},{"issue":"16","key":"1029_CR50","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.7150\/jca.31166","volume":"10","author":"Y Mo","year":"2019","unstructured":"Mo Y, et al. The role of Wnt signaling pathway in tumor metabolic reprogramming. J Cancer. 2019;10(16):3789.","journal-title":"J Cancer"},{"issue":"1","key":"1029_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-25672-6","volume":"8","author":"A Koval","year":"2018","unstructured":"Koval A, Katanaev VL. Dramatic dysbalancing of the Wnt pathway in breast cancers. Sci Rep. 2018;8(1):1\u201310.","journal-title":"Sci Rep"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-021-01029-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T18:06:11Z","timestamp":1675533971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-021-01029-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1186\/s12920-021-01029-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-136137\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]},"assertion":[{"value":"15 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Tabriz University of Medical Sciences, Tabriz, Iran with Ethics code IR.TBZMED.REC.1398.025. After explaining the study to participants, the written informed consent was obtained from all of them.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}